Sanofi wanted to measure the interaction kinetics between insulin and its two binding sites on the full-length insulin receptor, with the ultimate aim to optimize the clinical efficacy of novel insulin analogues
Biophysical experiments with any full-length transmembrane receptor are a known significant challenge.
Beactica’s team of highly skilled scientists developed an experimental design for SPR biosensor-based studies of the full-length insulin receptor.
The methods developed enable accurate measurements of interaction kinetics between insulin analogues and the two binding sites of full-length insulin receptor isoform A and B.
Results from the collaboration contributed towards the regulatory approval of Insulin lispro Sanofi®, a rapid-acting insulin biosimilar introduced on the market by Sanofi.
Korn M, Wohlfart P, Gossas T, Kullman-Magnusson M, Niederhaus B, Dedio J, Tennagels N (2019) Comparison of metabolic and mitogenic response in vitro of the rapid-acting insulin lispro product SAR342434, and US- and EU-approved Humalog®. Regulatory Toxicology and Pharmacology. 109:104497.
Sign up for the Beactica newsletter to receive our latest news and updates